As shown in Table 3, we found that the variant genotypes of SNP309 GT and TT were associated with a significantly decreased prostate cancer risk among carriers with p53 Pro alleles (OR = 0.79, 95% CI: 0.64-0.98, P for interaction = 0.0112). Here, TP53 is linked to prostate cancer.